drugset / Trial / NCT00563225

20 Week Bridging Study in Type II DM

NCT00563225

Phase 3 Completed 90 enrolled Sanofi
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A multicenter, non-comparative, one arm, open, phase III study to evaluate the efficacy and safety of insulin glargine on subjects with Type 2 Diabetes Mellitus

Timeline

Start
2002-10
Primary completion
Completion
2004-04

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin glargine Protein / enzyme biologic Subcutaneous